This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pedley, R. B. Articles by Begent, R. H. J. Search for Related Content PubMed PubMed Citation Articles by Pedley, R. B. Articles by Begent, R. H. J.

Enhancement of Antibody-directed Enzyme Prodrug Therapy in Colorectal Xenografts by an Antivascular Agent¹

Department of Oncology, Royal Free Campus, Royal Free and University College Medical School, University College London, London NW3 2PF [R. B. P., S. K. S., G. M. B., R. B., R. H. J. B.]: and Cancer Research Campaign Centre for Cancer Therapeutics at the Institute of Cancer Research, Sutton, Surrey, SM2 5NG [S. M. S., L. D., C. J. S.], United Kingdom

The irregular nature of solid tumor vasculature produces a heterogeneous distribution of antibody-targeted therapies within the tumor mass, which frequently results in reduced therapeutic efficacy. We have, therefore, combined two complementary therapies: Antibody-directed Enzyme Prodrug Therapy (ADEPT), which targets tumor cells, and an agent that selectively destroys tumor vasculature. A single i.p. dose (27.5 mg/kg) of the drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA), given to nude mice bearing the LS174T colorectal xenograft, destroyed all but a peripheral rim of tumor cells, without enhancing survival. The ADEPT system, in which a pretargeted enzyme activates a prodrug, consisted of the F(ab')₂ fragment of anti-carcinoembryonic antigen antibody A5B7 conjugated to the bacterial enzyme carboxypeptidase G2 and the prodrug 4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid, which was given i.p. in three doses of 500 mg/kg at 72, 84, and 96 h post-conjugate administration (25 units of carboxypeptidase G2). The antibody-enzyme conjugate could be selectively retained at approximately twice the control levels by administration of the antivascular agent at the time of optimal conjugate localization within the tumor (20 h post-conjugate administration), as demonstrated by gamma counting, phosphor plate image analysis, and active enzyme measurement. This resulted in significantly enhanced tumor growth inhibition in groups of six mice, compared to conventional ADEPT therapy, with no concomitant increase in systemic toxicity. In a separate experiment, aimed at trapping the prodrug within the tumor, a 16-fold increase over control values was produced (means, 44.8 versus 2.8 µg/g tumor) when DMXAA was given 4 h prior to 4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid. The therapeutic window was small, with no significant enhancement of prodrug retention when DMXAA was given at either earlier or later time points. This correlated with the time of vascular shut-down induced by the antivascular agent. We are currently investigating whether it is more advantageous to trap increased levels of conjugate or prodrug within the tumor for maximal enhancement of conventional ADEPT. These studies demonstrate that combined use of antibody-directed and antivascular therapies can significantly benefit the therapeutic outcome of either strategy alone.

This article has been cited by other articles:

				M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF]

				M. J. McKeage, P. Fong, M. Jeffery, B. C. Baguley, P. Kestell, M. Ravic, and M. B. Jameson 5,6-dimethylxanthenone-4-acetic Acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin. Cancer Res., March 15, 2006; 12(6): 1776 - 1784. [Abstract] [Full Text] [PDF]

				S. K. Sharma, R. B. Pedley, J. Bhatia, G. M. Boxer, E. El-Emir, U. Qureshi, B. Tolner, H. Lowe, N. P. Michael, N. Minton, et al. Sustained Tumor Regression of Human Colorectal Cancer Xenografts Using a Multifunctional Mannosylated Fusion Protein in Antibody-Directed Enzyme Prodrug Therapy Clin. Cancer Res., January 15, 2005; 11(2): 814 - 825. [Abstract] [Full Text] [PDF]

				M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF]

				K. F. Medzihradszky, D. I.R. Spencer, S. K. Sharma, J. Bhatia, R. B. Pedley, D. A. Read, R. H.J. Begent, and K. A. Chester Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein Glycobiology, January 1, 2004; 14(1): 27 - 37. [Abstract] [Full Text] [PDF]

				S. M. Galbraith, G. J.S. Rustin, M. A. Lodge, N. J. Taylor, J. J. Stirling, M. Jameson, P. Thompson, D. Hough, L. Gumbrell, and A. R. Padhani Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging J. Clin. Oncol., September 15, 2002; 20(18): 3826 - 3840. [Abstract] [Full Text] [PDF]

				L. H. Dang, C. Bettegowda, D. L. Huso, K. W. Kinzler, and B. Vogelstein Combination bacteriolytic therapy for the treatment of experimental tumors PNAS, November 20, 2001; (2001) 251543698. [Abstract] [Full Text] [PDF]

				G. Xu and H. L. McLeod Strategies for Enzyme/Prodrug Cancer Therapy Clin. Cancer Res., November 1, 2001; 7(11): 3314 - 3324. [Abstract] [Full Text] [PDF]

				R. B. Pedley, S. A. Hill, G. M. Boxer, A. A. Flynn, R. Boden, R. Watson, J. Dearling, D. J. Chaplin, and R. H. J. Begent Eradication of Colorectal Xenografts by Combined Radioimmunotherapy and Combretastatin A-4 3-O-Phosphate Cancer Res., June 1, 2001; 61(12): 4716 - 4722. [Abstract] [Full Text] [PDF]

				L. H. Dang, C. Bettegowda, D. L. Huso, K. W. Kinzler, and B. Vogelstein Combination bacteriolytic therapy for the treatment of experimental tumors PNAS, December 18, 2001; 98(26): 15155 - 15160. [Abstract] [Full Text] [PDF]